JWH-191

JWH-191 is a synthetic cannabinoid from the naphthoylindole family. It acts as a potent agonist at both the CB1 and CB2 cannabinoid receptors, with a slight selectivity for the CB2 receptor. JWH-191 is part of a series of compounds developed by Dr. John W. Huffman in the 1990s for research into the structure and function of the cannabinoid receptors.

Chemical Structure and Properties

JWH-191 is chemically classified as a naphthoylindole, which is characterized by a naphthalene group attached to an indole core. The full chemical name is (1-pentylindol-3-yl)-1-naphthalenylmethanone. The presence of the pentyl chain is a common feature in many synthetic cannabinoids, contributing to their lipophilicity and ability to cross the blood-brain barrier.

Pharmacology

JWH-191 binds to the cannabinoid receptors in the brain and peripheral tissues. It has a high affinity for the CB1 receptor, which is primarily responsible for the psychoactive effects of cannabinoids, and the CB2 receptor, which is more involved in immune modulation. The binding affinity of JWH-191 to these receptors is similar to that of other synthetic cannabinoids, making it a useful compound for studying the effects of cannabinoid receptor activation.

Legal Status

The legal status of JWH-191 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. It is often included in legislation targeting synthetic cannabinoids as a class.

Research and Applications

JWH-191, like other synthetic cannabinoids, is primarily used in scientific research to explore the cannabinoid system. It helps researchers understand the role of cannabinoid receptors in various physiological processes and the potential therapeutic applications of cannabinoid receptor modulation.

Safety and Toxicology

The safety profile of JWH-191 is not well-established, as it is primarily used in laboratory settings. However, synthetic cannabinoids as a class have been associated with a range of adverse effects, including cardiovascular and neurological symptoms. Caution is advised when handling these compounds in a research setting.

Also see

• Synthetic cannabinoids
• Cannabinoid receptor
• John W. Huffman
• Naphthoylindole
• CB1 receptor
• CB2 receptor